CLINICAL TRIALS
We thank patients and their families for their interest and participation in clinical trials.
Clinical trial participation makes research and advances in the treatment of cancer and infectious diseases possible.
When you join a clinical trial, you play an active role in your own health care, you gain access to new research treatments before they are widely available, and you help others by contributing to medical research.
By participating in a clinical trial you help advance medicine and improve lives.
-
Our cellular immunotherapy products are universal donor and off-the-shelf by design to improve clinical access with on-demand dosing for all patients in need.
-
More than 300 product infusions to date across 5 clinical trials with no unexpected serious adverse events or infusional toxicities.
OUR CLINICAL TRIALS
DILANUBICEL
A Multi-Center, Randomized, Controlled Trial of Standard of Care Intensive Chemotherapy ± Dilanubicel in Adults with De Novo and Treatment-Related Acute Myeloid Leukemia
PENDING
INDICATION: Newly diagnosed AML
Recent Granting of FDA Designations:
Granted February 26, 2024
Granted March 5, 2024
DVX201-COV-01
Phase 1
An Allogeneic Natural Killer (NK) Cell Therapy, in Subjects Hospitalized for COVID-19
OUT-LICENSED
INDICATION: COVID-19
OUT-LICENSED TO COEPTIS THERAPEUTICS
DVX201-AML-01
Phase 1
An Open-Label Pilot Multicenter Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome or High Risk Overlapping Myelodysplastic / Myeloproliferative Neoplasms
OUT-LICENSED
INDICATION: RELAPSED/REFRACTORY AML | HIGH RISK MDS/MPN
OUT-LICENSED TO COEPTIS THERAPEUTICS
ADDITIONAL RESOURCES
At Deverra, we understand how difficult it is to find reliable and credible information, therefore we are providing links to trusted and verified information about clinical trials, cancer, and Acute Myeloid Leukemia (AML). All content is reviewed by medical experts for accuracy.